Upload
bryson-timbers
View
219
Download
0
Tags:
Embed Size (px)
Citation preview
Judie Finesilver MRPharmS
e-Business Pharmacist
Commercial Medicines Unit,
Department of Health
07785 573 914
Update on barcodes & medicines-associated issues in NHS
February 23rd 2012
Franklin Room, IBM United Kingdom Limited, 76/78 Upper Ground,
What’s the current message ?
•NHS dm+d
•GS1
•EU Falsified Medicines Directive
•Projects from CMU
NHS Dictionary of Medicines and Devices – dm+d
•Website
•Name, strength, form of a medicine
•No ambiguity
•Enter the GTIN
http://www.dmd.nhs.uk/
No supply chain informaton.. No GTIN
GTIN Global Trader Item Number
GTIN- used to be known as EAN
Managed by GS1- Global Standards 1
Population of GTIN field currently ~ 20%
Working with BSA to appear in the browser
Link between clinical and supply chain will support patient safety
Example
Similar looking product- very different clinical action
Wrong label attached to product
What else could the barcode carry?
Newer and cleverer carriers.
QR code : 2D data matrix code
Quick Response Code
EU Falsified Medicines Directive
http://www.manufacturingchemist.com/news/article_page/EC_consults_on_Falsified_Medicines_Directive/71100
Safety Features?
Tamper-Evident Seal
Unique Identifier
Process
All POMs to be included and Medicines to be risk assessed for exclusion where the product is a POM or for inclusion where the product is a prescription medicine.
Risk assessments proposed to be based on cost, volume, risk to health.
Issues
•Cross industry issues: secondary care / homecare – who has responsibility for tracking and recording of codes?
•Issues in primary care: connectivity and networking issues raised – verification response time needs to be short
Discussion needed!
What are the most appropriate step(s) in the process for identification to happen ? –
•Point of dispensing only•Point of dispensing plus random points along the supply chain•Point of dispensing plus systematically along the supply chain Who is going to pay for this?What happens if legislation changes? Does this need enforcing – won’t happen otherwise?
Pan European issues:
•Europe are seeking harmonisation across Europe on standards, scanning mechanism (GS1 Or similar?) and repository approach
•When importing, products will need to be checked out of one countries repository and into another
•Who will hold the verification repository? options include: Centralised Europe repository, National Repository or a stakeholder owned repository (joint pharmacy and industry associations via not for profit organization). Complications include some countries may want to collaborate on setting up joint repositories and some may wish autonomy).•
Benefits
•Patient safety –the most important•Efficiency improvements (though wholesalers voiced concerns over additional workload if scanning each pack was imposed)•Aid investigation of errors•Aid product recall process•Having a unique identifier will ensure counterfeiters can’t
produce large batches of product – less cost effective •Companies that adopt 2D will be seen as having a differentiating factor when UK making purchasing decisions
Risk
manufacturers not willing to adopt will leave the UK market –
what impact will that have on UK supply chain?
Summary!
Current Projects for CMU
KPI reports-• JAC v4.47 and Crystal X1•Ascrbe v8
Stockholding Report-• 2 email addresses
Homecare
Homecare
Want to identify the homecare spend
•Request to hospital pharmacy to include the word (Home) in the supplier names
•And possibly to include the word (Home) in the product Description.
•Onerous•Difficult•Are you affected?
To Summarise
•NHS dm+d- add product into Data base
•GS1- not for profit global organisation- manage coding carriers
•EU Falsified Medicines Directive- tamper evidence and unique identification of product. Risk assessment for opt-out for all POMs
for opt-in for all Ps
•Projects for CMU- KPIs; Stockholding; Homecare
Judie Finesilver MRPharmS
e-Business Pharmacist
Commercial Medicines Unit,
Department of Health
07785 573 914
Update on barcodes & medicines-associated issues in NHS
February 23rd 2012
Franklin Room, IBM United Kingdom Limited, 76/78 Upper Ground,